By Dr. Lei Deng
University of Washington & Fred Hutch
Watch Dr. Lei Deng’s overview of the KEYNOTE-671 and NADIM II trials, with important implications for non small cell lung cancer treatment!
Overview of KEYNOTE-671 & NADIM II
Latest from Blog
By: Dr. Anish ShahBronx-Lebanon Hospital; Bronx, NY On April 5, 2024, the Food and Drug Administration granted
By: Dr. Arya Mariam Roy Roswell Park Comprehensive Cancer Center What are immune checkpoint inhibitors? Immune
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY On March 1, 2024, the U.S. Food and Drug Administration
By: Dr. Anish Shah Bronx-Lebanon Hospital; Bronx, NY The FDA gave its approval for the use of osimertinib
By: Dr. Anish ShahBronx-Lebanon Hospital; Bronx, NY On February 16, 2024, the U.S. Food and Drug Administration